Literature DB >> 19828525

Balancing innovation, access, and profits--market exclusivity for biologics.

Alfred B Engelberg1, Aaron S Kesselheim, Jerry Avorn.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19828525     DOI： 10.1056/NEJMp0908496

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

Review 1.  Controlled release of biologics for the treatment of type 2 diabetes.

Authors:  Caslin A Gilroy; Kelli M Luginbuhl; Ashutosh Chilkoti
Journal:  J Control Release       Date:  2015-12-02       Impact factor: 9.776

Review 2.  Unintended effects of orphan product designation for rare neurological diseases.

Authors:  Sinéad M Murphy; Araya Puwanant; Robert C Griggs
Journal:  Ann Neurol       Date:  2012-10       Impact factor: 10.422

3.  The prevalence and cost of unapproved uses of top-selling orphan drugs.

Authors:  Aaron S Kesselheim; Jessica A Myers; Daniel H Solomon; Wolfgang C Winkelmayer; Raisa Levin; Jerry Avorn
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

4.  Cost-effectiveness of proton beam therapy for intraocular melanoma.

Authors:  James P Moriarty; Bijan J Borah; Robert L Foote; Jose S Pulido; Nilay D Shah
Journal:  PLoS One       Date:  2015-05-18       Impact factor: 3.240

5.  Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application.

Authors:  Michael Wolzt; Ghazeleh Gouya; Michael Sator; Thomas Hemetsberger; Charlotte Irps; Manfred Rettenbacher; Brigitta Vcelar
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-01-30       Impact factor: 2.441

6.  Patents associated with high-cost drugs in Australia.

Authors:  Andrew F Christie; Chris Dent; Peter McIntyre; Lachlan Wilson; David M Studdert
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

Review 7.  Personalizing health care: feasibility and future implications.

Authors:  Brian Godman; Alexander E Finlayson; Parneet K Cheema; Eva Zebedin-Brandl; Inaki Gutiérrez-Ibarluzea; Jan Jones; Rickard E Malmström; Elina Asola; Christoph Baumgärtel; Marion Bennie; Iain Bishop; Anna Bucsics; Stephen Campbell; Eduardo Diogene; Alessandra Ferrario; Jurij Fürst; Kristina Garuoliene; Miguel Gomes; Katharine Harris; Alan Haycox; Harald Herholz; Krystyna Hviding; Saira Jan; Marija Kalaba; Christina Kvalheim; Ott Laius; Sven-Ake Lööv; Kamila Malinowska; Andrew Martin; Laura McCullagh; Fredrik Nilsson; Ken Paterson; Ulrich Schwabe; Gisbert Selke; Catherine Sermet; Steven Simoens; Dominik Tomek; Vera Vlahovic-Palcevski; Luka Voncina; Magdalena Wladysiuk; Menno van Woerkom; Durhane Wong-Rieger; Corrine Zara; Raghib Ali; Lars L Gustafsson
Journal:  BMC Med       Date:  2013-08-13       Impact factor: 8.775

8.  Is greater generic competition also linked to lower drug prices in South Korea?

Authors:  Kyung-Bok Son
Journal:  Health Econ Rev       Date:  2020-09-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.